Zoladex 3-Month Depot Implant Is Approved

February 1, 1996
Volume 23, Issue 5

WILMINGTON, Del--Zeneca Pharmaceuticals has received clearance from the FDA to market a new formulation of Zoladex (goserelin acetate implant) for the palliative treatment of advanced prostate cancer.

WILMINGTON, Del--Zeneca Pharmaceuticals has received clearancefrom the FDA to market a new formulation of Zoladex (goserelinacetate implant) for the palliative treatment of advanced prostatecancer.

The new formulation, a 10.8-mg goserelin acetate implant givenevery 3 months, offers greater convenience to patients choosingtreatment with a luteinizing-hormone-releasing hormone (LHRH)analog, the company said.

The original 1-month 3.6-mg formulation of Zoladex implants hasbeen available in the United States since 1989 for the treatmentof advanced prostate cancer. The drug has been marketed since1993 for the treatment of endometriosis, and it was recently clearedby the FDA for the treatment of advanced breast cancer in premenopausaland perimeno-pausal women.